PL2895188T3 - Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności - Google Patents

Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności

Info

Publication number
PL2895188T3
PL2895188T3 PL13838016T PL13838016T PL2895188T3 PL 2895188 T3 PL2895188 T3 PL 2895188T3 PL 13838016 T PL13838016 T PL 13838016T PL 13838016 T PL13838016 T PL 13838016T PL 2895188 T3 PL2895188 T3 PL 2895188T3
Authority
PL
Poland
Prior art keywords
high purity
correctly folded
excellent yield
folded etanercept
etanercept
Prior art date
Application number
PL13838016T
Other languages
English (en)
Polish (pl)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2895188(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences, Inc. filed Critical Coherus Biosciences, Inc.
Publication of PL2895188T3 publication Critical patent/PL2895188T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL13838016T 2012-09-11 2013-09-10 Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności PL2895188T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
EP13838016.7A EP2895188B1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Publications (1)

Publication Number Publication Date
PL2895188T3 true PL2895188T3 (pl) 2018-06-29

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13838016T PL2895188T3 (pl) 2012-09-11 2013-09-10 Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności

Country Status (33)

Country Link
US (6) US20140072560A1 (enExample)
EP (1) EP2895188B1 (enExample)
JP (3) JP2015533797A (enExample)
KR (2) KR102250937B1 (enExample)
CN (2) CN110051823A (enExample)
AR (1) AR092532A1 (enExample)
AU (2) AU2013315750B9 (enExample)
BR (1) BR112015005161A2 (enExample)
CA (1) CA2882551A1 (enExample)
CL (1) CL2015000572A1 (enExample)
CO (1) CO7400876A2 (enExample)
CY (1) CY1120062T1 (enExample)
DK (1) DK2895188T3 (enExample)
DO (1) DOP2015000055A (enExample)
EA (1) EA031324B1 (enExample)
EC (1) ECSP15014138A (enExample)
ES (1) ES2657377T3 (enExample)
HR (1) HRP20180182T1 (enExample)
HU (1) HUE036524T2 (enExample)
IL (2) IL237311B (enExample)
IN (1) IN2015KN00452A (enExample)
LT (1) LT2895188T (enExample)
MX (2) MX360044B (enExample)
NO (1) NO2972131T3 (enExample)
PE (2) PE20150996A1 (enExample)
PL (1) PL2895188T3 (enExample)
PT (1) PT2895188T (enExample)
RS (1) RS57013B1 (enExample)
SG (1) SG11201501460RA (enExample)
SI (1) SI2895188T1 (enExample)
SM (1) SMT201800163T1 (enExample)
TW (2) TWI716649B (enExample)
WO (1) WO2014043103A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US9302002B2 (en) 2011-10-18 2016-04-05 Coherus Biosciences, Inc. Etanercept formulations stabilized with combinations of sugars and polyols
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
PL2895188T3 (pl) * 2012-09-11 2018-06-29 Coherus Biosciences, Inc. Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności
AU2015273049B2 (en) * 2014-06-13 2019-11-14 Lupin Limited Process for the purification of TNFR:Fc fusion protein
ES2733298T3 (es) * 2014-07-18 2019-11-28 Sandoz Ag Cuantificación de TNFR2:Fc plegado erróneamente
US10988527B2 (en) 2014-12-31 2021-04-27 Lg Chem, Ltd. Method for preparing TNFR-Fc fusion protein containing target content of impurities
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
CA3005484A1 (en) * 2015-11-18 2017-05-26 Merck Patent Gmbh Opposite ph-salt gradients for improved protein separations
EP3377513A1 (en) * 2015-11-18 2018-09-26 Merck Patent GmbH Improved protein separation in ion exchange chromatography
BR112018075516A2 (pt) * 2016-06-17 2019-10-01 Genentech Inc purificação de anticorpos multiespecíficos
US20180110856A1 (en) * 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical Formulations and Methods of Making the Same
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US11697672B2 (en) * 2017-03-24 2023-07-11 Council Of Scientific & Industrial Research Process for the purification of recombinant antibody fragments
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
WO2021220251A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
AU2022236913A1 (en) * 2021-03-16 2023-10-26 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
AU2022369694B2 (en) * 2021-10-19 2025-10-09 Alteogen, Inc Method for purifying fusion protein having igg fc domain

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DE59109269D1 (de) 1990-06-28 2005-12-15 Hoechst Ag Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
CA2366785C (en) 1999-04-19 2012-02-07 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
WO2001058473A1 (en) 2000-02-10 2001-08-16 Wyeth Method of treating or inhibiting cellular injury or cell death
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
ES2370235T3 (es) 2001-02-23 2011-12-13 Immunex Corporation Recuperación eficaz de proteínas replegadas correctamente.
DK1478394T3 (da) 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
CN100563712C (zh) 2003-02-28 2009-12-02 阿雷斯贸易股份有限公司 肿瘤坏死因子结合蛋白的液体制剂
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
CA2533796A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
EP1680137B1 (en) 2003-10-14 2012-11-21 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication
CA2552639C (en) * 2004-02-27 2012-05-01 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
EP1720972B1 (en) 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
MX2008013535A (es) 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
US20080112953A1 (en) 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US9012180B2 (en) 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
BRPI0814252B8 (pt) 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
KR20150080038A (ko) 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
CA2717129A1 (en) * 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
JP5677943B2 (ja) * 2008-06-05 2015-02-25 アフィボディ・アーベーＡｆｆｉｂｏｄｙ Ａｂ ポリペプチド
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
WO2011017514A1 (en) 2009-08-07 2011-02-10 Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
WO2011049798A1 (en) * 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
CN102858952B (zh) 2010-04-26 2015-10-14 诺瓦提斯公司 改进的细胞培养基
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
SG187885A1 (en) 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
CA2813747A1 (en) * 2010-10-11 2012-04-19 Chen Wang Processes for purification of proteins
WO2012143418A1 (en) 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
AU2012279205B2 (en) * 2011-07-01 2017-08-31 Biogen Ma Inc. Arginine - free TNFR : Fc- fusion polypeptide compositions and methods of use
JP5897708B2 (ja) 2011-07-01 2016-03-30 アムジエン・インコーポレーテツド 哺乳類細胞培養物
AU2012282960A1 (en) * 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
ES2651483T3 (es) 2011-08-17 2018-01-26 Ares Trading S.A. Método para preparar la forma activa de la proteína de fusión TNRF-Fc
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9302002B2 (en) * 2011-10-18 2016-04-05 Coherus Biosciences, Inc. Etanercept formulations stabilized with combinations of sugars and polyols
CA2878508A1 (en) * 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
PL2895188T3 (pl) * 2012-09-11 2018-06-29 Coherus Biosciences, Inc. Prawidłowo pofałdowany etanercept o wysokiej czystości i doskonałej wydajności
CN106796355B (zh) * 2014-07-31 2020-09-22 Mtt创新公司 用于自由曲面透镜构造的数值方法：面积参数化自由曲面透镜构造
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
LT2895188T (lt) 2018-04-10
TW201425331A (zh) 2014-07-01
IL237311B (en) 2019-07-31
EA201590542A1 (ru) 2015-07-30
TWI609877B (zh) 2018-01-01
US20140072560A1 (en) 2014-03-13
ECSP15014138A (es) 2016-01-29
MX2015003090A (es) 2015-07-14
BR112015005161A2 (pt) 2017-07-04
RS57013B1 (sr) 2018-05-31
PT2895188T (pt) 2018-02-08
SG11201501460RA (en) 2015-04-29
SMT201800163T1 (it) 2018-05-02
IN2015KN00452A (enExample) 2015-07-17
AU2013315750A1 (en) 2015-03-05
TW201803593A (zh) 2018-02-01
AU2013315750B2 (en) 2018-07-12
AU2018247244A1 (en) 2018-11-01
US20190300601A1 (en) 2019-10-03
US20190300602A1 (en) 2019-10-03
CO7400876A2 (es) 2015-09-30
US20190300600A1 (en) 2019-10-03
EP2895188A4 (en) 2016-05-25
WO2014043103A1 (en) 2014-03-20
PE20200607A1 (es) 2020-03-10
US20180037642A1 (en) 2018-02-08
CN110051823A (zh) 2019-07-26
JP6913066B2 (ja) 2021-08-04
IL237311A0 (en) 2015-04-30
KR20200085937A (ko) 2020-07-15
EP2895188A1 (en) 2015-07-22
DK2895188T3 (en) 2018-02-26
MX2018012749A (es) 2020-11-12
JP2021100929A (ja) 2021-07-08
KR102133699B1 (ko) 2020-07-14
US20190330325A1 (en) 2019-10-31
JP2015533797A (ja) 2015-11-26
PE20150996A1 (es) 2015-08-01
US10954295B2 (en) 2021-03-23
EP2895188B1 (en) 2017-11-15
AU2013315750B9 (en) 2018-11-15
DOP2015000055A (es) 2015-04-30
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (enExample) 2018-04-21
AR092532A1 (es) 2015-04-22
CN104902914B (zh) 2019-01-01
US11001627B2 (en) 2021-05-11
HUE036524T2 (hu) 2018-07-30
KR20150056601A (ko) 2015-05-26
EA031324B1 (ru) 2018-12-28
US10947306B2 (en) 2021-03-16
AU2018247244B2 (en) 2020-05-28
JP2019038817A (ja) 2019-03-14
CN104902914A (zh) 2015-09-09
TWI716649B (zh) 2021-01-21
SI2895188T1 (en) 2018-05-31
CY1120062T1 (el) 2018-12-12
CA2882551A1 (en) 2014-03-20
IL267452B (en) 2021-05-31
US10954293B2 (en) 2021-03-23
US10954294B2 (en) 2021-03-23
IL267452A (en) 2019-08-29
HRP20180182T1 (hr) 2018-04-20
CL2015000572A1 (es) 2016-02-05
ES2657377T3 (es) 2018-03-05
MX360044B (es) 2018-10-19

Similar Documents

Publication Publication Date Title
IL267452B (en) Ethanercept is correctly folded with a high degree of cleanliness and excellent utilization
GB2503806B (en) Replacement-gate finfet structure and process
ZA201500231B (en) Photovoltaic frame fastener
GB201201506D0 (en) Photovoltaic panel circuitry
GB2509046B (en) Improvement in or relating to capsules
EP2855745A4 (en) METHODS RELATING TO ADALIMUM AB
EP2932375A4 (en) ADAPTATION OF OPPORTUNITY IN CONTEXT
EP2806761A4 (en) COMPONENTS OF A SEASACK
PT2806773T (pt) Módulo de infusão
PT2888284T (pt) Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
IL235425B (en) History of lysine-glutamic acid di-peptide
IL239824A0 (en) Use of inos inhibitors to increase viral survival in culture
EP2888277A4 (en) ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
ZA201503367B (en) Heteroaryl derivatives and uses thereof
GB2503225B (en) Balun
GB201210817D0 (en) Balun
EP2909309A4 (en) COMPOSITIONS AND METHODS FOR VITAMINOUS FERMENTATES
PT2906528T (pt) Processo para a obtenção de anilina pura
AU343221S (en) Zipper securing aid
AU343220S (en) Zipper securing aid
ZA201504198B (en) Methods for banana yield protection and enhancement
HUP1200259A2 (en) Shopping bag which can also be as litterbag
GB201201013D0 (en) Sleeping bag
IL212583A0 (en) Marketng by means of placing independent show cascs in shopping cenlers
GB201220447D0 (en) Releasable fastener